Tuesday, September 26, 2023


Biotechnology News Magazine

Global Insomnia Clinical Trial Pipeline Report 2021

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

January 27, 2021

Global Insomnia Clinical Trial Pipeline Highlights – 2021″ provides the most up-to-date information on key pipeline products in the global Insomnia market. It covers emerging therapies for Insomnia in active clinical development stages including early and late-stage clinical trials.

The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Insomnia pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Insomnia pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.


The report provides Insomnia pipeline products by the company.

Short-term Launch Highlights:

Find out which Insomnia pipeline products will be launched in the US and Ex-US till 2025.


  • Insomnia phase 3 clinical trial pipeline products
  • Insomnia phase 2 clinical trial pipeline products
  • Insomnia phase 1 clinical trial pipeline products
  • Insomnia preclinical research pipeline products
  • Insomnia discovery stage pipeline products
  • Insomnia pipeline products short-term launch highlights

Key Topics Covered:

1. Insomnia Pipeline by Stages

2. Insomnia Phase 3 Clinical Trial Insights

3. Insomnia Phase 2 Clinical Trial Insights

4. Insomnia Phase 1 Clinical Trial Insights

5. Insomnia Preclinical Research Insights

6. Insomnia Discovery Stage Insights

7. Appendix

8. Research Methodology

Countries Covered

  • Global
  • Europe
  • US
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Japan

For more information about this report visit here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine